Thank you, Stan and good afternoon. For the fiscal year ended April 30, 2021, consolidated revenue was $54.3 million, up 31% compared to $41.5 million for the same period of the prior fiscal year. The components of revenue are as follows. Revenue from commercial and U.S. government satellite programs was $27 million compared to $20.4 million for the same period of the prior fiscal year and accounted for approximately 50% of consolidated revenues compared to 49% for the prior fiscal year. Revenue on satellite payload contracts are recognized primarily under the percentage of completion method and recorded only in the FEI-New York segment. Revenue from non-space U.S. government and DoD customers, which are recorded in both the FEI-New York and FEI-Zyfer segments, were $27.8 million compared to $16.9 million in the same period of the prior fiscal year and accounted for approximately 46% of consolidated revenue compared to 41% for the prior fiscal year. Other commercial and industrial revenues were $2.5 million compared to $4.2 million in the prior fiscal year. Intersegment revenues are eliminated in consolidation. For the fiscal year ended April 30, 2021, gross profit and gross profit percentage increased significantly as compared to the prior fiscal year. The increase in gross profit and gross profit percentage was due to completion of several programs identified in prior periods that incurred higher engineering costs in their development phase and have since been completed or are near completion. For the fiscal year ended April 30, 2021 and 2020, selling and administrative expenses were approximately 24% and 28%, respectively of consolidated revenues. The increase in SG&A expense was mainly due to an increase in professional fees relating to litigation, deferred compensation and insurance expenses. R&D expense for the fiscal year ending April 30, 2021 and 2020 decreased to $4.7 million from $5.1 million, a decrease of $0.4 million and were 9% and 12% of consolidated revenue. The company’s R&D expense decreased year-over-year as previous R&D efforts have ended and turned into production. However, the company plans to continue to invest in R&D to keep its products at the state of the art. For the fiscal year ended April 30, 2021, the company recorded an operating loss of $1 million compared to $10.9 million in the prior year. The decrease in operating loss in the fiscal year ended April 30, 2021, reflects improvement in revenue, gross profit and gross profit percentage. Other income consists primarily of investments derived from the company’s holdings of marketable securities. For the fiscal year ended April 30, 2021, investment income includes $105,000 dividend from Morion compared to $250,000 dividend from Morion in the same period in fiscal ‘20. Included in other income for the fiscal year ended April 30, ‘21, was the collection of a $1 million note relating to the sale of Gillam in April of 2018. This yields pre-tax income of approximately $476,000 compared to a pre-tax loss of approximately $11.8 million in the prior year. For the fiscal year ending April 30, 2021, the company recorded a tax benefit of $204,000 compared to $1.7 million for the prior year. Consolidated net income for the fiscal year ending April 30, ‘21 was $680,000 or $0.07 per diluted share compared to a consolidated net loss of $10.3 million or $1.10 per share in the previous fiscal year. Our fully funded backlog at the end of April 2021 was approximately $40 million, up approximately $5 million from the previous year end April 30, 2020. The company’s balance sheet continues to reflect a strong working capital position of approximately $57 million at April 30, 2021 and a current ratio of approximately 6:1. Additionally, the company is debt free. The company believes that its liquidity is accurate to meet operating and investing needs for the next 12 months and the foreseeable future. I will turn the call back to Stan and we look forward to your questions shortly.